Table 1 Baseline characteristics of patient cohort
Characteristics | Group A: HCV/HIV co-infected patients | Group B: HCV mono-infected patients | p-values |
|---|---|---|---|
Patients, n | 88 | 84 | 0.666 |
Age (y), mean (min./max.) | 45 (26/64) | 45 (20/72) | 0.763 |
Sex, male/female (%) | 66/22 (75/25) | 52/32 (61/38) | 0.092 |
Genotype, n (%) | |||
1 | 37/88 (42) | 49/84 (58) | 0.033 |
2 | 3/88 (3) | 9/84 (10) | 0.060 |
3 | 25/88 (28) | 15/84 (17) | 0.102 |
4 | 2/88 (2) | 5/84 (5) | 0.222 |
Unknwon | 21/88 (23) | 6/84 (7) | 0.003 |
Liver biopsy, n (%) | 17/88 (19) | 36/84 (42) | 0.001 |
Fibrosis F3 – F4, n (%) | 6/17 (35) | 10/36 (27) | 0.251 |
HCV RNA in IU/ml, mean | 4 714 165 | 3 453 862 | 0.487 |
(min./max.) | (3/9 × 107) | (3/3 × 107) | |
HCV RNA > 800 000, n (%) | 66/88 (75) | 32/84 (38) | 0.001 |
HCV RNA < 800 000, n (%) | 22/88 (25) | 52/84 (61) | 0.001 |
Alanine transaminase in U/l, mean (min./max.) | 78 (3/526) | 105 (15/610) | 0.098 |
Start of heptitis C therapy, n (%) | 36 (40) | 52 (61) | 0.006 |
Liver biopsy, n (%) | 10 (27) | 27 (51) | 0.024 |
(Fibrosis F3 – F4, n (%) | 5 (13) | 8 (29) | 0.846 |
HCV RNA in IU/ml, mean | 4 799 700 | 3 222 000 | 0.530 |
(min./max.) | (800/9 × 107) | (3/2 × 107) | |
HCV RNA > 800 000, n (%) | 12 (33) | 21 (40) | 0.502 |
HCV RNA < 800 000, n (%) | 24 (66) | 31 (59) | 0.502 |
Alanine transaminase in U/l, mean (min./max.) | 94 (29/526) | 120 (18/610) | 0.321 |
Duration of therapy in weeks, mean (min./max.) | 33 (1/152) | 36 (10/128) | 0.496 |
Ribavirin (weight adapted) in mg/week, mean | 5764,28 | 7567,2 | 0.027 |
Peg-Interferon-alfa 2a, n (%) | 27/36 (75) | 41/52 (78) | 0.672 |
Peg-Interferon-alfa 2b, n (%) | 0/36 (0) | 3/52 (5) | 0.143 |
Non-peg-Interferon, n (%) | 3/36 (8) | 0/52 (0) | 0.034 |